These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 26257301

  • 1. ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.
    Muniyan S, Chen SJ, Lin FF, Wang Z, Mehta PP, Batra SK, Lin MF.
    Cell Signal; 2015 Nov; 27(11):2261-71. PubMed ID: 26257301
    [Abstract] [Full Text] [Related]

  • 2. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
    Miller DR, Ingersoll MA, Chatterjee A, Baker B, Shrishrimal S, Kosmacek EA, Zhu Y, Cheng PW, Oberley-Deegan RE, Lin MF.
    Free Radic Biol Med; 2019 Aug 01; 139():24-34. PubMed ID: 31100478
    [Abstract] [Full Text] [Related]

  • 3. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase.
    Yu P, Duan X, Cheng Y, Liu C, Chen Y, Liu W, Yin B, Wang X, Tao Z.
    Int J Mol Med; 2017 Nov 01; 40(5):1426-1434. PubMed ID: 28901378
    [Abstract] [Full Text] [Related]

  • 4. Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth.
    Chuang TD, Chen SJ, Lin FF, Veeramani S, Kumar S, Batra SK, Tu Y, Lin MF.
    J Biol Chem; 2010 Jul 30; 285(31):23598-606. PubMed ID: 20498373
    [Abstract] [Full Text] [Related]

  • 5. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells.
    Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, Lin MF.
    Oncogene; 2003 Feb 06; 22(5):781-96. PubMed ID: 12569372
    [Abstract] [Full Text] [Related]

  • 6. Role of protein S in castration-resistant prostate cancer-like cells.
    Ning P, Zhong JG, Jiang F, Zhang Y, Zhao J, Tian F, Li W.
    Endocr Relat Cancer; 2016 Aug 06; 23(8):595-607. PubMed ID: 27342144
    [Abstract] [Full Text] [Related]

  • 7. DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis.
    Lin HP, Ho HM, Chang CW, Yeh SD, Su YW, Tan TH, Lin WJ.
    FASEB J; 2019 Dec 06; 33(12):14653-14667. PubMed ID: 31693867
    [Abstract] [Full Text] [Related]

  • 8. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.
    Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, deVere White RW, Ghosh PM.
    Clin Cancer Res; 2011 Oct 01; 17(19):6218-28. PubMed ID: 21844010
    [Abstract] [Full Text] [Related]

  • 9. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.
    Benelli R, Barboro P, Costa D, Astigiano S, Barbieri O, Capaia M, Poggi A, Ferrari N.
    Int J Mol Sci; 2019 Dec 03; 20(23):. PubMed ID: 31816863
    [Abstract] [Full Text] [Related]

  • 10. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.
    Cai C, Portnoy DC, Wang H, Jiang X, Chen S, Balk SP.
    Cancer Res; 2009 Jun 15; 69(12):5202-9. PubMed ID: 19491261
    [Abstract] [Full Text] [Related]

  • 11. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM, Koochekpour S.
    Oncotarget; 2016 Sep 27; 7(39):64447-64470. PubMed ID: 27487144
    [Abstract] [Full Text] [Related]

  • 12. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Taylor CR, Datar R, Cote RJ.
    BJU Int; 2006 Jan 27; 97(1):170-8. PubMed ID: 16336351
    [Abstract] [Full Text] [Related]

  • 13. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase.
    Gesmundo I, Di Blasio L, Banfi D, Villanova T, Fanciulli A, Favaro E, Gamba G, Musuraca C, Rapa I, Volante M, Munegato S, Papotti M, Gontero P, Primo L, Ghigo E, Granata R.
    Cancer Lett; 2019 May 01; 449():252-262. PubMed ID: 30790678
    [Abstract] [Full Text] [Related]

  • 14. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Brizzolara A, Benelli R, Venè R, Barboro P, Poggi A, Tosetti F, Ferrari N.
    Cancer Lett; 2017 Aug 01; 400():9-17. PubMed ID: 28450158
    [Abstract] [Full Text] [Related]

  • 15. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.
    Bluemn EG, Spencer ES, Mecham B, Gordon RR, Coleman I, Lewinshtein D, Mostaghel E, Zhang X, Annis J, Grandori C, Porter C, Nelson PS.
    Mol Cancer Res; 2013 Jun 01; 11(6):568-78. PubMed ID: 23493267
    [Abstract] [Full Text] [Related]

  • 16. The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Mirzakhani K, Kallenbach J, Rasa SMM, Ribaudo F, Ungelenk M, Ehsani M, Gong W, Gassler N, Leeder M, Grimm MO, Neri F, Baniahmad A.
    Oncogene; 2022 Feb 01; 41(7):943-959. PubMed ID: 34667276
    [Abstract] [Full Text] [Related]

  • 17. Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling.
    Hu J, Zhu W, Wei B, Wen H, Mao S, Xu H, Hu M, Yang T, Jiang H.
    Anticancer Drugs; 2016 Nov 01; 27(10):944-52. PubMed ID: 27537398
    [Abstract] [Full Text] [Related]

  • 18. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W, Morales C, Cooke LS, Johnson B, Somer B, Mahadevan D.
    Oncotarget; 2015 Dec 08; 6(39):41976-87. PubMed ID: 26506516
    [Abstract] [Full Text] [Related]

  • 19. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J, McCubrey JA, Laidler P.
    Curr Med Chem; 2013 Dec 08; 20(1):144-57. PubMed ID: 23033951
    [Abstract] [Full Text] [Related]

  • 20. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.